Summary
VKTX at a glance
Viking Therapeutics (VKTX) holds a Quant grade of D (model v1, Oct 30), on a scale from S, the best, to D. It closed at $27.28 on Oct 30, 2026. The models produced no usable value for it on this snapshot.
Among the superinvestors tracked here, Bridgewater added. The latest filing is a 10-Q (quarterly report), filed Oct 29.
Price and model value
What the marks mean
Valuation
All 0 models →The models produced no usable value for VKTX on this snapshot.
No model could give VKTX a usable value.
- Other models
- —
- Wall St. target
- 85.00 68% below
- Past year
- —
- Valued as
- Loss-Making
Every model
Against its peers and its past
| VKTX | Peers' median | Own 5-yr median | |
|---|---|---|---|
| P/E · last fiscal year | — | 32.8× | — |
| Free cash flow yield | −8.0% | 3.2% | |
| Operating margin | — | 35.2% | |
| Revenue growth | — | 8.2% |
Peers are the comparable companies below; the five-year median is at each fiscal year's close.
What the price implies
No growth rate solves for the price: no positive fcf. The reverse DCF →
- Risk-free rate
- 4.94%
- Beta × equity premium
- 0.76 × 4.14%
- Cost of equity
- 8.10%
- Cost of debt
- 8.40%
- Equity weight
- 100%
- WACC
- 8.10%
Quant
Quant grade over time →Quant grade D from model v1, set before the Oct 30 open. S is the best, D the worst. What the grade means
- LLYS
- AMGNA
- PFEB
Growth and forecasts
Every estimate →| Revenue | Growth | EPS | Growth | Analysts | |
|---|---|---|---|---|---|
| FY2020 | $0 | — | -$0.50 | — | reported |
| FY2025 | $0 | — | -$3.19 | — | reported |
| FY2026E | $7.2M | — | -$5.32 | — | 9 |
| FY2027E | $7.3M | +2.5% | -$5.15 | — | 10 |
| FY2028E | $217.2M | +2854.9% | -$3.93 | — | 15 |
- Revenue, last 5 years
- —
- Consensus, next 3 years
- —
The analysts' estimates, as FMP collects them — their figures, not this site's. Reported EPS is GAAP diluted.
Financials
Full statements →| Latest | Year before | Change | |
|---|---|---|---|
| Revenue | $0 | $0 | n/m |
| Operating income | -$648.6M | -$274.8M | n/m |
| Net income | -$627.2M | -$237.4M | n/m |
| Free cash flow | -$462.6M | -$224.6M | n/m |
| Diluted EPS | -$5.41 | -$2.12 | n/m |
- Cash and investments
- $959.8M
- Total debt
- $254.7M
Profitability and health
Every ratio →Operating margin 0.0% in fiscal 2025, against 0.0% in 2021; net cash of $705.1M at the latest quarter.
| FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | Trend | |
|---|---|---|---|---|---|---|
| Gross margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Net margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Return on equity | −27.2% | −47.4% | −24.7% | −12.5% | −56.3% | |
| Debt to equity | 0.00× | 0.01× | 0.00× | 0.00× | 0.00× | |
| Interest coverage | -3093.44× | -1192.46× | -1145.76× | -1605.54× | 0.00× | |
| Current ratio | 23.98× | 7.61× | 19.19× | 33.09× | 9.33× |
Peers
Peers in full →VKTX beside 4 comparable companies, chosen by business, not by industry label.
| Company | Market value | P/E | FCF yield | Gross margin | Op. margin | Revenue growth | Valuation | Quant |
|---|---|---|---|---|---|---|---|---|
| VKTX Viking Therapeutics, Inc. | $3.5B | n/m | −8.0% | — | — | — | – | D |
| LLY Eli Lilly and Company | $1.3T | 61.8× | 0.7% | 83.0% | 45.6% | +44.7% | D | S |
| AMGN Amgen Inc. | $251.9B | 32.8× | 3.2% | 70.8% | 29.1% | +9.9% | B | A |
| NVO Novo Nordisk A/S | $176.4B | n/m | — | 81.0% | 41.3% | +6.4% | – | – |
| PFE Pfizer Inc. | $174.0B | 22.4× | 5.2% | 70.3% | 24.7% | −1.7% | S | B |
Ownership
Every holder →| Bridgewater | added | $3.4M |
- Lian BrianJul 29 · President & CEO−$4.9M
Wall Street
Every firm →3 firms published a price target in the last 90 days: the median is $85.00, 212% above the close.
Third-party ratings and targets, quoted as the firms published them — not this site's view.
Analyst actions
News and filings
All news →About
Company profile →Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administered, tissue and receptor-selective agonist of the thyroid hormone receptor beta (TRß). This compound is currently progressing through Phase IIb clinical trials, targeting both non-alcoholic steatohepatitis (NASH) in biopsy-confirmed patients and non-alcoholic fatty liver disease (NAFLD). Viking's pipeline also features VK5211, an oral, non-steroidal selective androgen receptor modulator undergoing Phase II studies for individuals recuperating from non-elective hip fracture surgery. Additionally, VK0612, an oral drug candidate for type 2 diabetes, is poised to enter Phase IIb trials. The firm is also developing VK0214, another orally active, tissue and receptor-selective TRß agonist, specifically aimed at X-linked adrenoleukodystrophy. Founded in 2012, Viking Therapeutics is headquartered in San Diego, California.
- CEO
- Brian Lian
- Employees
- 53
- Headquarters
- San Diego, CA
- Listed
- 2015
Research on VKTX
Model estimates and grades for research reference only, not investment advice. Every model rests on assumptions that may not match what happens; each section is explained in the manual.